Off-label use of maraviroc in clinical practice.
Maraviroc is a first-in-class selective CCR5 antagonist only approved in combination with other antiretrovirals for the treatment of HIV-infection. However, sometimes, off-label prescribing is necessary. In this regard, interesting data have been obtained with maraviroc from studies using murine models. In human daily clinical practice there are many researching areas of interest where CCR5 could play an important role. Nowadays few clinical trials are evaluating maraviroc's role in non-HIV-infected patients but there are many open issues that need to be answered about CCR5 antagonists. In this article we review some of them.
a Infectious Diseases Area , Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR) , Logroño , Spain.
José-Ramón
JR
Blanco
b Oncology Area , Center for Biomedical Research of La Rioja (CIBIR) , Logroño , Spain.
Laura
L
Ochoa-Callejero
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D065100:CCR5 Receptor Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000077592:Maraviroc; D051379:Mice; D056687:Off-Label Use; D012507:Sarcoidosis / Q000188:drug therapy* / Q000473:pathology; D014230:Triazoles / Q000627:therapeutic use*
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc
CCR5 antagonist; maraviroc; off-label use